DK2262364T3 - Oxadiazoanthracenforbindelser for the treatment of diabetes - Google Patents

Oxadiazoanthracenforbindelser for the treatment of diabetes Download PDF

Info

Publication number
DK2262364T3
DK2262364T3 DK09718287.7T DK09718287T DK2262364T3 DK 2262364 T3 DK2262364 T3 DK 2262364T3 DK 09718287 T DK09718287 T DK 09718287T DK 2262364 T3 DK2262364 T3 DK 2262364T3
Authority
DK
Denmark
Prior art keywords
phenyl
diaza
oxo
oxa
hexahydro
Prior art date
Application number
DK09718287.7T
Other languages
Danish (da)
English (en)
Inventor
Adnan M M Mjalli
Dharma Rao Polisetti
Thomas Scott Yokum
Mustafa Guzel
Christopher Behme
Stephen Thomas Davis
Kalpathy Santhosh
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Application granted granted Critical
Publication of DK2262364T3 publication Critical patent/DK2262364T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK09718287.7T 2008-03-07 2009-03-06 Oxadiazoanthracenforbindelser for the treatment of diabetes DK2262364T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (1)

Publication Number Publication Date
DK2262364T3 true DK2262364T3 (en) 2016-03-21

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09718287.7T DK2262364T3 (en) 2008-03-07 2009-03-06 Oxadiazoanthracenforbindelser for the treatment of diabetes

Country Status (17)

Country Link
US (7) US7727983B2 (enExample)
EP (1) EP2262364B1 (enExample)
JP (1) JP5382952B2 (enExample)
KR (1) KR101616737B1 (enExample)
CN (1) CN101959405B (enExample)
AU (1) AU2009221722B2 (enExample)
BR (1) BRPI0910282A2 (enExample)
CA (1) CA2716664C (enExample)
DK (1) DK2262364T3 (enExample)
EA (1) EA018225B1 (enExample)
ES (1) ES2567451T3 (enExample)
IL (1) IL207570A (enExample)
MA (1) MA32175B1 (enExample)
MX (1) MX2010009752A (enExample)
NZ (1) NZ587343A (enExample)
WO (1) WO2009111700A2 (enExample)
ZA (1) ZA201006367B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111700A2 (en) 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
CN102378574B (zh) * 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5694561B2 (ja) 2010-12-23 2015-04-01 ファイザー・インク グルカゴン受容体モジュレーター
WO2012096824A1 (en) * 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
KR101638671B1 (ko) 2011-02-08 2016-07-11 화이자 인코포레이티드 글루카곤 수용체 조절자
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2674951T3 (es) * 2012-03-22 2018-07-05 Transtech Pharma, Llc Sales de tris(hidroximetil)aminometano de un agonista de GLP1R de molécula pequeña y composiciones farmacéuticas y usos de las mismas
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
KR102165434B1 (ko) * 2013-01-17 2020-10-14 브이티브이 테라퓨틱스 엘엘씨 2형 당뇨병 및 다른 장애의 치료를 위한 glp1r 작용제 및 메트포민의 조합 및 이것들의 사용법
AU2015292356B2 (en) * 2014-07-25 2020-02-06 Receptos Llc Novel GLP-1 receptor modulators
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
CA3090823A1 (en) 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
AU2019382642B2 (en) 2018-11-22 2025-05-29 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CU20210083A7 (es) * 2019-04-12 2022-05-11 Qilu Regor Therapeutics Inc Agonistas de glp-1r
CN115461344B (zh) 2020-04-01 2024-01-12 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
WO2021196951A1 (zh) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4159737A4 (en) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE
TW202210461A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種(s)—2—胺基—3—(4—(2,3—二甲基吡啶—4—基)苯基)丙酸甲酯二酸鹽的製備方法
JP2023539584A (ja) 2020-09-01 2023-09-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
US20230382899A1 (en) * 2020-10-14 2023-11-30 Qilu Regor Therapeutics Inc. Crystal forms of glp-1r agonists and uses thereof
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
US20240246959A1 (en) 2020-11-27 2024-07-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and medical use thereof
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するglp-1受容体作動薬を含有する医薬組成物
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CN117098758A (zh) 2021-06-24 2023-11-21 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法
JPWO2024063143A1 (enExample) 2022-09-22 2024-03-28
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd 1,4−ベンゾオキサジン誘導体,その製造法およびそれを含有する医薬用組成物
WO1997012853A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
HUP0203431A3 (en) * 1999-12-03 2003-11-28 Kyoto Pharma Ind Novel heterocyclic compounds and salts thereof and pharmaceutical compositions containing and use of the same
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) * 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
CN100432056C (zh) * 2003-03-26 2008-11-12 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
WO2009111700A2 (en) * 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
CN101959405A (zh) 2011-01-26
US20100324033A1 (en) 2010-12-23
US20150087640A1 (en) 2015-03-26
MX2010009752A (es) 2010-09-30
CA2716664C (en) 2016-10-11
US20130317015A1 (en) 2013-11-28
BRPI0910282A2 (pt) 2015-09-01
EP2262364A2 (en) 2010-12-22
US8933222B2 (en) 2015-01-13
AU2009221722A1 (en) 2009-09-11
US20110039837A1 (en) 2011-02-17
EA201071045A1 (ru) 2011-02-28
IL207570A (en) 2014-03-31
CN101959405B (zh) 2014-07-02
US20090306063A1 (en) 2009-12-10
MA32175B1 (fr) 2011-03-01
ZA201006367B (en) 2011-05-25
EP2262364B1 (en) 2016-03-02
EA018225B1 (ru) 2013-06-28
WO2009111700A3 (en) 2010-03-04
WO2009111700A2 (en) 2009-09-11
KR20100131455A (ko) 2010-12-15
KR101616737B1 (ko) 2016-05-02
US7727983B2 (en) 2010-06-01
US20140187769A1 (en) 2014-07-03
US7906507B2 (en) 2011-03-15
CA2716664A1 (en) 2009-09-11
US8524708B2 (en) 2013-09-03
US20100197677A1 (en) 2010-08-05
ES2567451T3 (es) 2016-04-22
IL207570A0 (en) 2010-12-30
NZ587343A (en) 2012-05-25
US7790714B2 (en) 2010-09-07
JP2011513431A (ja) 2011-04-28
HK1148435A1 (en) 2011-09-09
US8703766B2 (en) 2014-04-22
EP2262364A4 (en) 2012-04-04
AU2009221722B2 (en) 2014-12-18
JP5382952B2 (ja) 2014-01-08
US9120813B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
DK2262364T3 (en) Oxadiazoanthracenforbindelser for the treatment of diabetes
JP5755217B2 (ja) 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
HK1148435B (en) Oxadiazoanthracene compounds for the treatment of diabetes
HK1164050B (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof